Quantitative CT showed that the anabolic group did not lose muscle volume during the first 12 months whereas the control group did (p<0.01). There was less bone loss in the proximal tibia in the anabolic group than in the control group. The speed of gait and the Harris hip score were significantly better in the anabolic group after six and 12 months.
Functional recovery after fracture of the hip is often incomplete. A catabolic state develops after operation 1 and malnutrition, which is either present or develops after surgery, [2] [3] [4] [5] contributes to a poor outcome. Many patients cannot return to normal life 6, 7 and the mortality rate is high. 6, 8, 9 Patients who sustain fractures of the hip lose body-weight and lean body mass after operation. 1, 10 Muscle weakness and the associated loss of mobility increase the risk of falls, 11 further fractures 12 and functional dependency. 13 A decrease in lean body mass and protein deficiency leads to generalised weakness, an impaired immune response and slower wound healing. 14, 15 The effect of a small dose of anabolic steroids in these patients has not been evaluated although it has been shown to restore bodyweight in other catabolic states such as acquired immune deficiency syndrome and chronic obstructive pulmonary disease. 16, 17 Both muscles and protein are lost and there is a decrease in bone mineral density (BMD) after fracture of the hip. 1, 18 This decrease is most pronounced in the trabecular bone in the ipsilateral leg, 19 but is also present in the contralateral hip. 18 A low BMD is associated with an increased risk of fracture. 20 The role of synthetic anabolic steroids in the treatment of postmenopausal and post-traumatic osteoporosis is uncertain. Earlier studies on elderly women with osteoporosis have shown positive effects of treatment with nandrolone decanoate on the BMD in the distal forearm and proximal femur. 21, 22 Women show an age-related decline in endogenous androgens which persists into advanced age. 23, 24 It has been suggested that a decline of free testosterone may influence the development of osteoporosis in women. 25 A recent pilot study has suggested that dihydroepiandrosterone, a precursor of both oestrogens and androgens, has a positive effect on both BMD and lean body mass in the elderly. 26 Elderly women are also prone to deficiency of vitamin D because of reduced exposure to sunlight, decreased synthesis of vitamin D in the skin, low vitamin D in the diet and a decline of the renal synthesis of metabolites of vitamin D. [27] [28] [29] [30] [31] Low serum levels of vitamin D may lead to secondary hyperparathyroidism and bone loss and have been demonstrated in patients with fractures of the hip. [32] [33] [34] [35] Recent data have also shown an increased prevalence of secondary hyperparathyroidism in these patients. 34, 35 The loss of BMD and lean body mass may be modified by treatment with anabolic drugs. We have investigated whether an anabolic steroid given with vitamin D and calcium could reduce postoperative catabolism and give a better outcome after a fracture of the hip without serious adverse effects.
Patients and Methods
Between January 1994 and February 1998 we studied 63 women over 65 years of age, who were living independently in their own homes. Those who had been treated with bone-active drugs during the previous years, had a metabolic disease which could influence bone density or were smokers were excluded, as were those who had previously sustained a fracture of the contralateral hip or had cerebrovascular disease affecting mobility. Patients were also excluded if they had significant liver disease, renal calculi, hypercalcaemia, a renal impairment with a serum creatinine >150 mmol/1dm 3 , uncontrolled hypertension, heart failure, abnormal thyroid function, alcohol abuse or dementia. The study was approved by the Committee for Medical Ethics of Karolinska Hospital.
Patients with subcapital fractures (35) underwent fixation with two parallel screws and those with pertrochanteric fractures (28) with a sliding nail-plate. Four patients died during the year of treatment, two from each group. Two patients were subsequently excluded because of poor health. Four did not wish to participate after surgery, two from each group.
The patients who discontinued treatment were analysed by intention to treat, except for two who were followed for seven and eight months. One developed progressive cholangitis and the other a primary hyperparathyroidism. Seven patients, four from the anabolic group and three from the control group, developed pseudarthrosis or avascular necrosis, and underwent arthroplasty. All were followed for one year with appropriate measurements, but were not included in the assessment of clinical function.
The patients were allocated by sealed envelopes to receive either treatment for one year with nandrolone decanoate (25 mg intramuscularly every third week), a daily supplement of 1alpha-hydroxylated vitamin D3 (alphacalcidol 0.25 g) and calcium (500 mg), or to receive calcium only.
Of the 63 patients included in the study, 32 were allocated to the anabolic group and 31 to the control group (Table I ); 57 patients were followed for six months (30 from the anabolic and 27 from the control group) and 51 for 12 months (25 from the anabolic and 26 from the control group). Nandrolone decanoate is a testosterone analogue (estrene derivate) which is thought to have anabolic effects with less masculinising side-effects, such as hoarseness and increased growth of facial hair. It was given in a dose which was half that recommended when the study was instigated in order to minimise side-effects. The intramuscular injections were given by a nurse. A low dose of calcium was chosen for the control group since it has been shown to have a minor effect on BMD when given alone. Alphacalcidol, currently only given to patients with renal failure, was used because renal function is often reduced in the elderly. It was also commonly used for elderly osteoporotic patients when the study was started.
The patients were followed up at three, six, nine and 12 months. Blood and urine samples were obtained at each visit. Bone densitometry and body composition were measured before treatment and after six and 12 months, when assessment also included the Harris hip score, 36 pain assessment using a visual analogue score (VAS), 37 gait speed 38 and an activities of daily living (ADL) score. 39 The ADL index according to Katz et al 39 is a six-grade scale which reflects bathing, dressing, toilet, transfer, continence and feeding. The Harris hip score includes several parameters with a maximum of 100 points; the absence of pain scores 44, normal function 47, absence of deformity 4 and range of movement 5 points. 36 The VAS is a graphic presentation in which the patient indicates the severity of pain on a line which is 10 cm long; 0 equals no pain and 10 very severe pain. 37 The speed of gait was evaluated in a corridor 30 m long. The patients used their usual walking aids and were instructed to walk at a comfortable speed.
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Measurement of BMD and thigh muscle volume. Bone density was measured two to three days after surgery and after six and 12 months. A real BMD, expressed as 'areal density' (g/cm 2 ), of the contralateral hip was determined by dual-energy x-ray absorptiometry (DXA) using DPX-L (Lunar Corporation, Madison, Wisconsin). The results are given for three regions of interest; the neck, Ward's triangle and the trochanteric area. The standard deviation of BMD in patients with hip fracture was compared with the mean level in young adults and age-matched normal subjects, and expressed as the T and Z scores, respectively. The precision error of the method was 2% for measurements of the femoral neck in this group of patients, which is similar to that of previous reports. 40, 41 Quantitative CT. We used CT (General Electric Pace Plus, Milwaukee, Wisconsin) for volumetric measurement of the BMD (g/cm 3 ) of the mid-femur, the distal femur and the proximal tibia. The femur was scanned 20 cm and 5 cm proximal to the distal limit of the lateral femoral condyle and the tibia 2 cm below this point. Three circular regions of interest were chosen in the cortical bone in the midfemur. The mean value was estimated as the BMD at this site. By tracing around the distal femur and proximal tibia the bone density and area in that region were determined. The volumes of the thigh muscle were also measured 20 cm proximal to the distal limit of the lateral condyle. There is a difference in x-ray attenuation between fat, bone and muscle and, by using thresholds for each, the computer calculates the volumes. We calculated the bone mass as the BMD multiplied by the bone volume at each site. In order to elucidate whether the muscle had gained normal muscle tissue or only intracellular fluid, the relative mass of muscle was calculated as the attenuation value multiplied by the volume of the muscle. The CT precision error had earlier been estimated at 2% for BMD in the mid-femur, 4% for the distal femur, 5% for the proximal tibia and 3% for muscle volume of the mid-femur using the same equipment in our department. 42 These values were similar to those previously reported. 43, 44 Quantitative ultrasound. For measurements of the heel we used an Achilles ultrasound device (Lunar Corporation, Madison, Wisconsin). The results are expressed as the speed of sound (SOS, m/s), broad-band US attenuation (BUA, dB/mHz). The stiffness index (%) is an arbitrary unit expressed by an algorithm of the combination of SOS and BUA (BUA-50) ϫ 0.67 ϩ (SOS+1380) ϫ 0.28). The precision error of this method has been found to be 2% to 4% 45 and is similar to our measurements.
The thickness of the triceps skinfold, reflecting subcutaneous fat mass, 46 was determined with a calliper before the start of treatment and after six and 12 months. The body mass index (BMI, weight in kg/height in m 2 ) was also calculated. Both routine laboratory tests and measurements of biochemical bone markers were done on admission, and after six and 12 months (Table II) 
Results
The Harris hip scores were significantly better in the anabolic group after six and 12 months. The gait speed was faster after six months in the anabolic group and continued to be better after 12 months, as was the Katz index (Table  III) . The anabolic group had a decrease of subcutaneous fat according to the measurements of the triceps skinfold, both after six and 12 months (Table IV) and there was a significant difference compared with the control group at six months which had a slight increase of subcutaneous fat. The BMI was unchanged after six months in both groups. After 12 months the BMI was 22.8 in the anabolic group and 23.9 in the control group.
CT showed that the anabolic group did not lose muscle volume in the operated leg during the first 12 months whereas the control group did (p < 0.01). We also found a significant increase in muscle volume in the contralateral leg in the anabolic group (Table IV) . Estimations of relative muscle mass showed similar differences between the groups (Table IV) . * S-balp, bone-specific alkaline phosphatase; S-PICP, C-terminal propeptide of type-I collagen; S-ICTP, C-terminal telopeptide of type-I collagen; U-Dpd, deoxypyridinoline There was a preserving effect on BMD in all sites in the anabolic group. In the contralateral tibia there was a decrease in the control group at both six and 12 months. There was less reduction in the anabolic group compared with the control group, at six months in the ipsilateral proximal tibia and at 12 months in the ipsilateral distal femur (Table V) . There was no difference between the two groups with regard to changes during the first 12 months in the mid-femoral region. There were no significant absolute differences in bone volume or changes with the passage of time between the two groups. The changes in the bone mineral content followed the BMD findings at all sites.
There was a small rise in plasma calcium levels during treatment for 12 months, from 2.19 to 2.46 mmol/l for the control group and from 2.20 to 2.48 mol/l for the anabolic group. The other laboratory measurements remained within normal levels. There was a significant increase for all bone markers between admission and the follow-up at six months for both groups (Table II) , but no significant changes between six and 12 months, the levels of the markers of both bone formation and resorption remaining high compared with those on admission in both groups. There was no significant difference in the levels of bone markers between the two groups and after six and 12 months (Table  II) .
Three patients had side-effects such as hoarseness or increased facial hair from the treatment.
Discussion
Many functionally independent people who are living at home before fracture of the hip require placement in a nursing home and do not regain their previous level of function. 6 One important predictor for discharge after a hip fracture is the ability to walk after operation 47 and it is therefore important to evaluate whether more active postoperative treatment can improve the long-term outcome. A variety of functional tests is available which correlate well with lean body mass and muscle mass. 48 The anabolic group had better function and walking ability after six and 12 months compared with the control group. Few studies have evaluated the use of anabolic steroids on function after a hip fracture. A pilot study of 19 patients followed for four weeks showed, contrary to our findings, no detectable benefits for treatment with nandrolone decanoate, 49 but the period of study was short. A double-blind study showed better mobility and less pain in patients with vertebral fractures after treatment with this drug compared with alphacalcidol. 50 It is not clear whether treatment with anabolic steroids increases muscle volume and strength in all young healthy athletes, but it is effective in those who have trained to the point at which they are in a catabolic state. 51 We used a much smaller dose than that used by athletes to see if it could preserve lean body mass in elderly patients with fractures of the hip who often are in a catabolic state after surgery. We found a change in body composition, with an increase in muscle volume in the contralateral leg and a preserving effect on the muscle volume in the ipsilateral leg in the anabolic group after six and 12 months. There was a simultaneous decrease in subcutaneous fat in the anabolic group. Similar findings have been reported in postmenopausal osteoporotic women, with an increase in lean body mass and a corresponding decrease in fat mass measured by DXA after treatment with a dose of nandrolone which was twice that used in our study. 52 Recently, Villareal et al 26 described similar treatment with dihydroepiandrosterone in elderly patients. Apart from an increase in BMD there was an altered body composition with a reversal of age-related changes, a net gain in lean body mass and a decrease in fat mass. These results support our findings which show a reversal of the catabolic state which normally follows a fracture of the hip involving a loss of BMD, a decrease in lean body mass and an increase in fat mass. 1, 10, 18 In order to establish whether the increase in the muscle volume merely reflected fluid retention, 53 we also measured the attenuation value and relative muscle mass and found the same differences between the two groups, indicating an increase of muscle tissue rather than oedema. Whether this increase in muscle volume is accompanied by an increase in strength has not been proven. It is uncertain whether the preserving effect on the volume of thigh muscle was an effect of the anabolic steroids alone since the administration of vitamin D to patients with established deficiency of vitamin D restores muscle strength. 54 It has been suggested that the weakness associated with ageing is partly due to inadequate levels of vitamin D. No relationship between vitamin D and muscle strength was found in healthy elderly women, 55 and this was confirmed in a randomised, double-blind study in which vitamin D was given to mobile healthy elderly subjects with relatively normal vitamin D status. 56 Vitamin D and calcium were found to have a protective effect against fractures of the hip in elderly patients in nursing homes, 57 but lower doses of vitamin D did not reduce the incidence of fractures in independent patients. 58 The reason for the reduced incidence in the residents of nursing-homes is unclear since treatment with vitamin D does not generate the expected increase in BMD, but merely reduces bone loss. 59 It may be that the positive effect of vitamin D on muscle reduces the incidence of injuries caused by falls. 60 The prevalence of deficiency of vitamin D and the low calcium absorption which increases with age, has geographical, racial and seasonal differences. 27, 29, 61 Probably most important, however, is the difference between mobile and institutionalised patients. 29, [62] [63] [64] The variable effects of supplementation with vitamin D on bone and muscles may be related to the selection of patients in the different studies.
Most studies use supplements with vitamin D while we used alphacalcidol, which is an active metabolite of vitamin D. Currently, it is only recommended for patients with renal failure since earlier studies have shown that higher doses of metabolites of vitamin D may cause hypercalcaemia. Mild hypercalcaemia occurred in only two patients receiving alphacalcidol in our study. One of these was later shown to have primary hyperparathyroidism which contributed to the hypercalcaemia. Studies on the effect of alphacalcidol on BMD have yielded conflicting results, but have shown a decrease in spinal bone loss and a reduction of the incidence of vertebral fractures in elderly women. [65] [66] We found that the anabolic group, treated with a lower dose of nandrolone decanoate than in earlier studies, lost less BMD than the control group, particularly in the distal femur and proximal tibia which are areas with mostly trabecular bone. There were also positive effects on BMD in the femoral diaphysis, which is mostly cortical bone, on the injured side after both six and 12 months. Bone remodelling is a surface-based process and the metabolic activity of cancellous bone is tenfold greater than that at cortical sites. 67 It is thus not surprising that we found preserving effects on BMD mainly in the sites with trabecular bone. An early study reported an increase in BMC of the distal forearm after one year which was not acompanied by an increase in BMD, and the authors suggested that nandrolone decanoate may act by increasing bone size. 68 This was not confirmed by us or others. 69 Need et al 21 found an increase in BMC in the forearm when giving 50 mg of nandrolone decanoate every third week for one year, compared with a decrease in a control group, but they had a high incidence of hoarseness while we had a low incidence using half the dose. Another study matched pairs of postmenopausal women with osteoporosis to hormone replacement therapy with or without this drug. There was a significant increase in BMC and BMD of the lumbar spine in the third year in the group receiving the steroid. This effect was still apparent 12 months after stopping treatment. 70 Long-lasting beneficial effects have also been reported by others. 71 Although several studies have described the changes in BMD after treatment with nandrolone decanoate, these results are difficult to interpret and compare because of the use of different methods of measuring densitometry at different sites. Our results suggest that it may be possible to preserve BMD with a dose which is not associated with significant side-effects. Whether our findings of a beneficial effect on trabecular bone were due to an increased formation or mineralisation or by reduced resorption of bone is unclear. Both formation and resorption markers of bone were increased after six months and remained high after 12 months, indicating an increased turnover of bone after a fracture of the hip, as we have previously reported. 72 The high bone turnover could be associated with post-traumatic osteopenia and fracture healing. There was no significant difference in the levels of bone markers between the two groups despite the anabolic treatment and the differences noted in BMD. Minor differences in the levels of bone markers may not be detectable because of the already increased bone turnover induced by the trauma. This study suggests that a low dose of nandrolone decanoate in combination with a low dose of alphacalcidol and calcium has a positive effect on body composition, BMD and the clinical function in elderly women after fracture of the hip. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
